InnoCare Pharma Limited provided earnings guidance for the year ended December 31, 2021. For the period, the group expects to record a consolidated net loss of not more than approximately RMB 100 million as compared with a consolidated net loss of approximately RMB 464 million for the same period in 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.38 HKD | +1.39% | -4.16% | -36.43% |
05-31 | InnoCare Pharma CEO Boosts Shareholding to 7.16% | MT |
05-31 | InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.43% | 1.1B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended December 31, 2021